Acorah Software Products - Accounts Production 16.0.110 false true 31 March 2023 1 April 2022 false 1 April 2023 31 March 2024 31 March 2024 12462233 Dr Andrew Bottley iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 12462233 2023-03-31 12462233 2024-03-31 12462233 2023-04-01 2024-03-31 12462233 frs-core:Non-currentFinancialInstruments 2024-03-31 12462233 frs-core:ShareCapital 2024-03-31 12462233 frs-core:RetainedEarningsAccumulatedLosses 2024-03-31 12462233 frs-bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 12462233 frs-bus:FilletedAccounts 2023-04-01 2024-03-31 12462233 frs-bus:SmallEntities 2023-04-01 2024-03-31 12462233 frs-bus:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 12462233 frs-bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 12462233 frs-bus:OrdinaryShareClass2 2023-04-01 2024-03-31 12462233 frs-bus:OrdinaryShareClass2 2024-03-31 12462233 frs-bus:Director1 2023-04-01 2024-03-31 12462233 frs-core:Non-currentFinancialInstruments 1 2024-03-31 12462233 frs-countries:EnglandWales 2023-04-01 2024-03-31 12462233 2022-03-31 12462233 2023-03-31 12462233 2022-04-01 2023-03-31 12462233 frs-core:Non-currentFinancialInstruments 2023-03-31 12462233 frs-core:ShareCapital 2023-03-31 12462233 frs-core:RetainedEarningsAccumulatedLosses 2023-03-31 12462233 frs-bus:OrdinaryShareClass2 2022-04-01 2023-03-31 12462233 frs-core:Non-currentFinancialInstruments 1 2023-03-31
Registered number: 12462233
Ribocell Ltd
Financial Statements
For The Year Ended 31 March 2024
AVL Business Advisory Limited
Contents
Page
Balance Sheet 1
Notes to the Financial Statements 2
Page 1
Balance Sheet
Registered number: 12462233
2024 2023
Notes £ £ £ £
CURRENT ASSETS
Cash at bank and in hand 10 10
10 10
NET CURRENT ASSETS (LIABILITIES) 10 10
TOTAL ASSETS LESS CURRENT LIABILITIES 10 10
Creditors: Amounts Falling Due After More Than One Year 4 (8,266 ) (7,295 )
NET LIABILITIES (8,256 ) (7,285 )
CAPITAL AND RESERVES
Called up share capital 5 10 10
Profit and Loss Account (8,266 ) (7,295 )
SHAREHOLDERS' FUNDS (8,256) (7,285)
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Dr Andrew Bottley
Director
19 December 2024
The notes on page 2 form part of these financial statements.
Page 1
Page 2
Notes to the Financial Statements
1. General Information
Ribocell Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12462233 . The registered office is The Ingenuity Centre University of Nottingham, Triumph Road, Nottingham, Nottinghamshire, NG7 2TU.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2023: NIL)
- -
4. Creditors: Amounts Falling Due After More Than One Year
2024 2023
£ £
Convertible loan notes 8,266 7,295
The Company entered into an agreement on 10th February 2022 with the University of Nottingham to create unsecured convertible loan notes up to a value of £100,000. The University can subscribe for loan notes in integral multiples of £1 and proceeds will be used to support patent and management costs relating to Ribocell technology for a period up to 30 April 2023. 
The loan notes are interest-bearing at a rate of 3% above Bank of England base rate and are convertible on completion of the next relevant Fund Raising, or on or after 30th April 2023. The Loan Notes and associated interest may also be redeemed at the discretion of the University.
On the 17th July 2024 the above agreement was extended until August 2025.
At 31 March 2024, £7,295 of Loan Notes had been subscribed for (2023: £7,295).
5. Share Capital
2024 2023
Allotted, called up and fully paid £ £
10,000 Ordinary A shares of £ 0.001 each 10 10
Page 2